nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—NF2—meningioma	0.0728	0.0728	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—TSHB—meningioma	0.0286	0.0286	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CST3—meningioma	0.0206	0.0206	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—SMO—meningioma	0.0185	0.0185	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—ERBB2—meningioma	0.0171	0.0171	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—ERBB2—meningioma	0.0134	0.0134	CbGpPWpGaD
Pimecrolimus—FKBP1A—TOR Signaling—AKT1—meningioma	0.0129	0.0129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PGR—meningioma	0.0119	0.0119	CbGpPWpGaD
Pimecrolimus—MTOR—CD28 dependent PI3K/Akt signaling—AKT1—meningioma	0.0112	0.0112	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—PDGFB—meningioma	0.011	0.011	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—ERBB2—meningioma	0.0107	0.0107	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—PDGFB—meningioma	0.00992	0.00992	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—PDGFB—meningioma	0.00968	0.00968	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—PDGFB—meningioma	0.00961	0.00961	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—PDGFB—meningioma	0.00939	0.00939	CbGpPWpGaD
Pimecrolimus—MTOR—FSH signaling pathway—AKT1—meningioma	0.00917	0.00917	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—PLAU—meningioma	0.00911	0.00911	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFR2 mediated vascular permeability—AKT1—meningioma	0.0089	0.0089	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—AKT1—meningioma	0.00842	0.00842	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—ERBB2—meningioma	0.00824	0.00824	CbGpPWpGaD
Pimecrolimus—MTOR—CD28 co-stimulation—AKT1—meningioma	0.008	0.008	CbGpPWpGaD
Pimecrolimus—MTOR—Alpha 6 Beta 4 signaling pathway—AKT1—meningioma	0.00781	0.00781	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AP1B1—meningioma	0.00771	0.00771	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AP1B1—meningioma	0.00767	0.00767	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—meningioma	0.00748	0.00748	CbGpPWpGaD
Pimecrolimus—MTOR—Class I PI3K signaling events mediated by Akt—AKT1—meningioma	0.00745	0.00745	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PDGFB—meningioma	0.00742	0.00742	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—ERBB2—meningioma	0.00738	0.00738	CbGpPWpGaD
Pimecrolimus—MTOR—TOR Signaling—AKT1—meningioma	0.00728	0.00728	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—AKT1—meningioma	0.00712	0.00712	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PDGFB—meningioma	0.0071	0.0071	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PDGFB—meningioma	0.00698	0.00698	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—AKT1—meningioma	0.00697	0.00697	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00693	0.00693	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—PDGFB—meningioma	0.00667	0.00667	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—ERBB2—meningioma	0.00665	0.00665	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—PDGFB—meningioma	0.00664	0.00664	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PDGFB—meningioma	0.0066	0.0066	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—PDGFB—meningioma	0.00657	0.00657	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—AKT1—meningioma	0.00656	0.00656	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—ERBB2—meningioma	0.00649	0.00649	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PDGFB—meningioma	0.00648	0.00648	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—ERBB2—meningioma	0.00644	0.00644	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—AKT1—meningioma	0.00632	0.00632	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—PTEN—meningioma	0.0063	0.0063	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB2—meningioma	0.00629	0.00629	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—meningioma	0.00623	0.00623	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PDGFB—meningioma	0.00618	0.00618	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PDGFB—meningioma	0.00618	0.00618	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PDGFB—meningioma	0.00618	0.00618	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PDGFB—meningioma	0.00613	0.00613	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PDGFB—meningioma	0.00607	0.00607	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PDGFB—meningioma	0.00605	0.00605	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—meningioma	0.00593	0.00593	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.00591	0.00591	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—AKT1—meningioma	0.00588	0.00588	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PDGFB—meningioma	0.00572	0.00572	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—PTEN—meningioma	0.00567	0.00567	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—PTEN—meningioma	0.00554	0.00554	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—PTEN—meningioma	0.00549	0.00549	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PDGFB—meningioma	0.00548	0.00548	CbGpPWpGaD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—meningioma	0.00543	0.00543	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—meningioma	0.00537	0.00537	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—PTEN—meningioma	0.00537	0.00537	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—PTEN—meningioma	0.00537	0.00537	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD34—meningioma	0.00521	0.00521	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—meningioma	0.00519	0.00519	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—AKT1—meningioma	0.00519	0.00519	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CTSL—meningioma	0.00517	0.00517	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—meningioma	0.00512	0.00512	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—ERBB2—meningioma	0.00497	0.00497	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CTSL—meningioma	0.00497	0.00497	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—meningioma	0.00476	0.00476	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—AKT1—meningioma	0.00471	0.00471	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—ERBB2—meningioma	0.00468	0.00468	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AP1B1—meningioma	0.00467	0.00467	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CST3—meningioma	0.00456	0.00456	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—meningioma	0.00454	0.00454	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—AKT1—meningioma	0.00448	0.00448	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—AKT1—meningioma	0.00448	0.00448	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—ERBB2—meningioma	0.00447	0.00447	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—meningioma	0.00445	0.00445	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—ERBB2—meningioma	0.00445	0.00445	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—ERBB2—meningioma	0.00443	0.00443	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—ERBB2—meningioma	0.0044	0.0044	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—AKT1—meningioma	0.00438	0.00438	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—AKT1—meningioma	0.00438	0.00438	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00434	0.00434	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—AKT1—meningioma	0.00433	0.00433	CbGpPWpGaD
Pimecrolimus—MTOR—SREBP signalling—AKT1—meningioma	0.00433	0.00433	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AP1B1—meningioma	0.00432	0.00432	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—PTEN—meningioma	0.00424	0.00424	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PDGFB—meningioma	0.00421	0.00421	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—ERBB2—meningioma	0.00414	0.00414	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—ERBB2—meningioma	0.00414	0.00414	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.00414	0.00414	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—ERBB2—meningioma	0.00411	0.00411	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—meningioma	0.00407	0.00407	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—PTEN—meningioma	0.00406	0.00406	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—ERBB2—meningioma	0.00405	0.00405	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—AKT1—meningioma	0.00405	0.00405	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00403	0.00403	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—PTEN—meningioma	0.00401	0.00401	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—PTEN—meningioma	0.00399	0.00399	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—meningioma	0.00384	0.00384	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—ERBB2—meningioma	0.00383	0.00383	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—PTEN—meningioma	0.00383	0.00383	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—PTEN—meningioma	0.00381	0.00381	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—PTEN—meningioma	0.00379	0.00379	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—PTEN—meningioma	0.00379	0.00379	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—PTEN—meningioma	0.00377	0.00377	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—PTEN—meningioma	0.00376	0.00376	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.0037	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.0037	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—AKT1—meningioma	0.0037	0.0037	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00367	0.00367	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—meningioma	0.00366	0.00366	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.00363	0.00363	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—PTEN—meningioma	0.00353	0.00353	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00353	0.00353	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—PTEN—meningioma	0.00353	0.00353	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—PTEN—meningioma	0.0035	0.0035	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—PTEN—meningioma	0.00347	0.00347	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—PTEN—meningioma	0.00346	0.00346	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.00341	0.00341	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TSHB—meningioma	0.00337	0.00337	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—PTEN—meningioma	0.00327	0.00327	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—AKT1—meningioma	0.00327	0.00327	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—AKT1—meningioma	0.00319	0.00319	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—AKT1—meningioma	0.00317	0.00317	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD34—meningioma	0.00316	0.00316	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00313	0.00313	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.00309	0.00309	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—AKT1—meningioma	0.00309	0.00309	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—meningioma	0.00305	0.00305	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CTSL—meningioma	0.00301	0.00301	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—AKT1—meningioma	0.00288	0.00288	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SMO—meningioma	0.00287	0.00287	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—ERBB2—meningioma	0.00282	0.00282	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PGR—meningioma	0.00275	0.00275	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—meningioma	0.00274	0.00274	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HES1—meningioma	0.00269	0.00269	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CST3—meningioma	0.00257	0.00257	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—AKT1—meningioma	0.00244	0.00244	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PTEN—meningioma	0.00241	0.00241	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PDGFB—meningioma	0.0024	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—meningioma	0.0024	0.0024	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—meningioma	0.00234	0.00234	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—meningioma	0.00231	0.00231	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PDGFB—meningioma	0.00231	0.00231	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—meningioma	0.0023	0.0023	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PDGFB—meningioma	0.0023	0.0023	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—meningioma	0.00221	0.00221	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—meningioma	0.0022	0.0022	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—meningioma	0.00219	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—meningioma	0.00219	0.00219	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—meningioma	0.00218	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—meningioma	0.00216	0.00216	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.00213	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—meningioma	0.00204	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—meningioma	0.00204	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00204	0.00204	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—meningioma	0.00202	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—meningioma	0.002	0.002	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—meningioma	0.00199	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TSHB—meningioma	0.0019	0.0019	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—meningioma	0.00188	0.00188	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HES1—meningioma	0.00188	0.00188	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.0018	0.0018	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—meningioma	0.00175	0.00175	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SMO—meningioma	0.00161	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—meningioma	0.00161	0.00161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDGFB—meningioma	0.00161	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PGR—meningioma	0.00155	0.00155	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—meningioma	0.00155	0.00155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—meningioma	0.00154	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HES1—meningioma	0.00151	0.00151	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDGFB—meningioma	0.0014	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—meningioma	0.00139	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—meningioma	0.00137	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—meningioma	0.00132	0.00132	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—meningioma	0.00131	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFB—meningioma	0.00129	0.00129	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—meningioma	0.00108	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—meningioma	0.00106	0.00106	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—meningioma	0.000938	0.000938	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALAD—meningioma	0.000934	0.000934	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—meningioma	0.000919	0.000919	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFB—meningioma	0.000905	0.000905	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—meningioma	0.000866	0.000866	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—meningioma	0.0008	0.0008	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—meningioma	0.000791	0.000791	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—meningioma	0.00076	0.00076	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—meningioma	0.000757	0.000757	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—meningioma	0.000738	0.000738	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—meningioma	0.000627	0.000627	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—meningioma	0.000606	0.000606	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TSHB—meningioma	0.000602	0.000602	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—meningioma	0.00053	0.00053	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—meningioma	0.000517	0.000517	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—meningioma	0.000461	0.000461	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—meningioma	0.000426	0.000426	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—meningioma	0.000353	0.000353	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—meningioma	0.000298	0.000298	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—meningioma	0.000164	0.000164	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—meningioma	9.45e-05	9.45e-05	CbGpPWpGaD
